Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gastric inhibitory polypeptide receptor (GIPR) directly induces energy accumulation in adipose tissue in vitro. However, the importance of the direct effect of GIPR signaling on adipose tissue in vivo remains unclear. In the current study, we generated adipose tissue-specific GIPR knockout (GIPR
adipo-/-
) mice and investigated the direct actions of GIP in adipose tissue. Under high-fat diet (HFD)-fed conditions, GIPR
adipo-/-
mice had significantly lower body weight and lean body mass compared with those in floxed GIPR (GIPR
fl/fl
) mice, although the fat volume was not significantly different between the two groups. Interestingly, insulin resistance, liver weight, and
hepatic steatosis
were reduced in HFD-fed GIPR
adipo-/-
mice. Plasma levels of interleukin-6 (IL-6), a proinflammatory cytokine that induces insulin resistance, were reduced in HFD-fed GIPR
adipo-/-
mice compared with those in HFD-fed GIPR
fl/fl
mice.
Suppressor of cytokine signaling 3
(
SOCS3
) signaling is located downstream of the IL-6 receptor and is associated with insulin resistance and
hepatic steatosis
. Expression levels of
SOCS3
mRNA were significantly lower in adipose and liver tissues of HFD-fed GIPR
adipo-/-
mice compared with those of HFD-fed GIPR
fl/fl
mice. Thus, GIPR signaling in adipose tissue plays a critical role in HFD-induced insulin resistance and
hepatic steatosis
in vivo, which may involve IL-6 signaling.
...
PMID:Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice. 2809 57
